CrossrefInfokarte
Cardiovascular safety of romosozumab versus alendronate in postmenopausal women with severe osteoporosis: a propensity-matched real-world study
Journal of Bone and Mineral Metabolism · 2026-10-30
DOI: 10.1007/s00774-026-01775-3 ↗Abstract
Kein Abstract verfügbar.
EUVIMED